Resultsbee.com

Results For: "Lymphoma Treatment"
Sponsored Links
  • 01

    News Delivered to your Browserstar-rating

    newsprompt.co | Breaking News - Across all newspapers. No signup required.
    See It
  • 02

    Fact-based blogs every daystar-rating

    blogbliss.net | Stay Informed: Daily Fact-Based Blogs to Enlighten Your Mind
    See It

Interested in "Lymphoma Treatment"?

Lymphoma is a form of cancer that affects the lymphatic system, the body's disease-fighting network consisting of multiple lymph nodes and vessels that move lymph fluid across the body. Lymph fluid contains infection-fighting white blood cells called lymphocytes, which can become infected and turn cancerous instead of protecting the body from infec

Read More

LYMPHOMA TREATMENT

Lymphomas is a form of carcinoma that start in white blood cells called lymphocytes. There are 2 main types of lymphoma. Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). They behave, spread, and respond to treatment differently, so it’s important for you to know which one you have.

Types of Hodgkin lymphoma

Classic Hodgkin lymphoma

Classic Hodgkin lymphoma (cHL) accounts for about 95% of all cases of Hodgkin lymphomas in developed countries.

The carcinoma cells in cHL are called Reed-Sternberg cells. These cells are usually an abnormal type of B lymphocyte. Enlarged lymph nodes in people with cHL usually have a small number of Reed-Sternberg cells and a large number of surrounding normal immune cells. These other immune cells make up most of the enlarged lymph nodes.

Classic HL has 4 subtypes:

  • Nodular sclerosis Hodgkin lymphoma: This is the most common type of Hodgkin disease in developed countries. It is most common in teens and young adults, but it can occur in people of any age. It tends to start in lymph nodes in the neck or chest.
  • Mixed cellularity Hodgkin lymphoma: This is the second most common type and is seen mostly in older adults (although it can occur at any age). It can start in any lymph node but most often occurs in the upper half of the body.
  • Lymphocyte-rich Hodgkin lymphoma: This subtype usually occurs in the upper half of the body and is rarely found in more than a few lymph nodes.
  • Lymphocyte-depleted Hodgkin lymphoma: This is the least common form of Hodgkin disease. It is seen mainly in older people. It is more likely to be advanced when first found, in lymph nodes in the abdomen as well as in the spleen, liver, and bone marrow.

Nodular lymphocyte predominant Hodgkin lymphoma

Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) accounts for about 5% of cases. The carcinoma cells in NLPHL are large cells called popcorn cells (because they look like popcorn), which are variants of Reed-Sternberg cells.

NLPHL usually starts in lymph nodes in the neck and under the arm. It can occur in people of any age, and is more common in men than in women. This type of HL is treated differently from the classic types.

Causes

Scientists aren’t sure what causes Hodgkin’s lymphoma. But it begins when an infection-fighting cell called a lymphocyte develops a genetic mutation. The mutation tells the cell to multiply rapidly, causing many diseased cells that continue multiplying.

The mutation causes a large number of oversized, abnormal lymphocytes to accumulate in the lymphatic system, where they crowd out healthy cells and cause the signs and symptoms of Hodgkin’s lymphoma.

Various types of Hodgkin’s lymphoma exist. Your diagnosis is based on the types of cells involved in your disease and their behavior. The type of lymphoma you are diagnosed with determines your treatment options.

Symptoms

Signs and symptoms of Hodgkin’s lymphoma may include:

  • Painless swelling of lymph nodes in your neck, armpits or groin
  • Persistent fatigue
  • Fever
  • Night sweats
  • Unexplained weight reduction
  • Severe itching


Diagnosis

To diagnose HD, your health care provider will perform a physical exam and ask you about your health history. Your health care provider will also order certain tests so they can make a proper diagnosis. The following tests may be done:

  • imaging tests, such as X-rays or CT scans
  • lymph node biopsy, which involves removing a piece of lymph node tissue to test for the presence of abnormal cells
  • blood tests, such as a complete blood count (CBC), to measure levels of red blood cells, white blood cells, and platelets
  • immunophenotyping to determine the type of lymphoma cells that are present
  • lung function tests to determine how well your lungs are working
  • an echocardiogram to determine how well your heart is working
  • bone marrow biopsy, which involves the removal and examination of marrow inside your bones to see if the carcinoma has spread

Treatment

Treatment for HD typically depends on the stage of the disease. The main treatment options are chemotherapy and radiation.

Radiation therapy uses high-energy beams of radiation to destroy carcinoma cells. Chemotherapy involves the use of treatments that can kill carcinoma cells. Chemotherapy may be given orally or injected through a vein, depending on the specific treatment.

Radiation therapy alone may be sufficient for treating early stage NLPHL. If you have NLPHL, you may only need radiation since the condition tends to spread more slowly than classic HD. In advanced stages, targeted therapeutic treatment may be added to your chemotherapy regimen.

Immunotherapy or a stem cell transplant may also be used if you don’t respond to chemotherapy or radiation. A stem cell transplant infuses healthy cells called stem cells into your body to replace the infected cells in your bone marrow.

After treatment, your health care provider will want to follow up with you on a regular basis. Be sure to keep all your appointments and follow your health care providers instructions.

Risks of treatment for Hodgkin’s disease

Treatments for HD can have long-term side effects and can increase your risk of developing other seriou health conditions. HD treatments may increase your risk of:

  • second relapses
  • infertility
  • infections
  • thyroid problems
  • lung damage

You should get regular mammograms and heart disease screenings, keep up with vaccinations, and avoid smoking.

It’s also important to attend regular follow-up appointments with your health care provider. Make sure to tell them about any concerns you may have about long-term side effects and what you can do to help reduce your risk.

Refine by

Reset All
Brands
  • 15503 Ventura Blvd. Suite 150,Encino,CA

    Dr Palaskas joined the Encino Cancer Care practice in 2017 and is excited to help fulfill the mission of UCLA in bringing access to clinical trials and academic-center level care to the Encino community. He is a Clinical Instructor of Medicine at the David Geffen School of Medicine at UCLA and clinician-investigator. He completed his Hematology/Oncology fellowship at UCLA and is a graduate of the Specialty Training and Advanced Research Program. Dr Palaskas is a native of the American Midwest but spent many years in Europe, including attending medical school in Thessaloniki, Greece. He trained in Internal Medicine at St Elizabeth?s Medical Center in Boston, a TUFTS University affiliate. Prior to his Fellowship at UCLA, he cared for complicated cancer patients with multiple medical problems at a Partners Healthcare Long Term Acute Care facility in Cambridge MA. As a member of the Ingo Mellinghoff lab at UCLA and later at Memorial Sloan Kettering Cancer Center in New York, he contributed to preclinical research into mechanisms of tumor resistance to targeted therapies, new metabolic inhibitors targeting a mutated version of the enzyme IDH, and treatment targets for lymphomas of the brain. An IDH inhibitor is now approved by the FDA for the treatment of relapsed and refractory acute myeloid leukemias. Pulse-dose lapatinib is currently being tested in a phase II clinical trial sponsored by the Jonson Comprehensive Cancer Center at UCLA in patients with an aggressive form of brain tumors and expected to be completed in 2019. The substantial activity of Ibrutinib in a phase I trial in relapsed and refractory brain lymphomas was reported in Cancer Discovery. Dr Palaskas is now interested in using metabolic interventions to improve the already promising activity of cancer immunotherapies.

    (181) 899 - 5804

    16 MI
  • 5215 Torrance Boulevard #300,Torrance,CA

    Jose Carrillo, MD, is a board-certified neurologist and neuro-oncologist specializing in the diagnosis and treatment of primary & secondary brain tumors, including glioblastoma multiforme, primary CNS lymphoma, meningioma, and brain metastases, as well as the neurologic complications of cancer. In addition, Dr. Carrillo is involved in the enrollment of patients into several clinical trials. Dedicated to advancing medicine, Dr. Carrillo is a strong proponent of leading-edge research in the diagnosis, treatment and prevention of all types of CNS tumors, including metastatic brain & spine tumors, primary malignant brain and spinal cord tumors, primary benign or lowgrade brain or spine tumors, and skull base and pituitary tumors. His particular research interests involve neuroimaging brain tumor features and molecular markers pertaining to treatment and survival.

    (142) 421 - 2536

    9 MI
  • 2020 Santa Monica Boulevard Suite 600,Santa Monica,CA

    Dr. Patricia Young is a hematologist and medical oncologist who practices in Santa Monica and Westwood. She has a specialized interest in hematologic malignancies, including leukemia and lymphoma, and is a faculty member in UCLA Health's Stem Cell Transplant Program. She values a patient-centered approach to medicine, and always involves patients and their families in treatment decisions. She is board certified in internal medicine, hematology and medical oncology, and is also an assistant…

    (131) 082 - 9547

    7 MI
  • 200 Medical Plaza Driveway Suite 120,Los Angeles,CA

    Dr. Josh Sasine is a hematologist and oncologist at UCLA specializing in the treatment of hematologic malignancies, including hematopoietic stem cell transplantation (bone marrow transplantation), cellular therapy, and clinical trials of novel therapeutics. He is the Director of the Chimeric Antigen Receptor T-Cell (CAR T) Program. He treats patients with blood and bone marrow disorders such as leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma, amyloidosis, aplastic anemia, Waldenstrom Macroglobulinemia, polycythemia vera, primary myelofibrosis, paroxysmal nocturnal hemoglobinuria (PNH), and others. Dr. Sasine is a physician-scientist and has an active scientific research program studying how cancer cells in the bone marrow get by supported by their non-cancerous neighboring cells; the goal of the work is to discover new medicines by inhibiting these interactions.

    (131) 020 - 6690

    10 MI
  • 4133 Redwood Ave #2008,Los Angeles,CA

    Urbane Doggie is a Dog Trainer located in Los Angeles, CA and has been servicing all of Los Angeles and the surrounding areas for many years. We specialize

    (131) 077 - 3598

    5 MI
  • 1044 W Hillcrest Blvd,Inglewood,CA

    In order for us to provide a better environment for the dogs, we have created a new and improved dog hotel in 2009.

    (131) 065 - 0449

    7 MI

Most Popular Questions